KYM Biosciences

AstraZeneca strengthens its oncology R&D with in-licensing of CMG901 from China-based biotech KYM Biosciences
Medical Marketing and Media
Fri, 02/24/23 - 09:16 am
AstraZeneca
CMG901
antibody-drug conjugate
gastric cancer
KYM Biosciences
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
Fierce Biotech
Thu, 02/23/23 - 10:00 am
AstraZeneca
Claudin18.2
KYM Biosciences
antibody-drug conjugate
pancreatic cancer